GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » Total Liabilities

Genfit (Genfit) Total Liabilities : $115.51 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Genfit Total Liabilities?

Genfit's Total Liabilities for the quarter that ended in Dec. 2023 was $115.51 Mil.

Genfit's quarterly Total Liabilities declined from Jun. 2023 ($129.35 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($115.51 Mil).

Genfit's annual Total Liabilities declined from Dec. 2021 ($183.76 Mil) to Dec. 2022 ($128.19 Mil) and declined from Dec. 2022 ($128.19 Mil) to Dec. 2023 ($115.51 Mil).


Genfit Total Liabilities Historical Data

The historical data trend for Genfit's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Total Liabilities Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 250.88 261.01 183.76 128.19 115.51

Genfit Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 128.19 129.35 - 115.51

Genfit Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genfit's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.963+(67.888+-0.0010000000000179
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+4.591+1.067)
=115.51

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=189.61-74.101
=115.51

Genfit's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.963+(67.888+-0.0010000000000179
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+4.591+1.067)
=115.51

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=189.61-74.101
=115.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genfit Total Liabilities Related Terms

Thank you for viewing the detailed overview of Genfit's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit (Genfit) Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.